STOCK TITAN

Coherus Oncology (CHRS) SEC Filings, Jan-Apr 2026

CHRS NASDAQ

Coherus Oncology, Inc. filings document an oncology operating company with Nasdaq-listed common stock and disclosures tied to LOQTORZI commercialization, antibody immunotherapy development and capital formation. Form 8-K reports cover operating results and business updates, preliminary financial information, clinical supply arrangements involving tagmokitug, and equity transactions under shelf registration, at-the-market and underwritten public offering structures.

Proxy and other filings describe board elections, executive compensation, equity awards, shareholder voting matters, registered securities, governance practices, risk disclosures and the company's capital structure, including common stock issuance and offering-related agreements.

Rhea-AI Summary

Coherus Oncology, Inc. filed preliminary proxy materials for its virtual 2026 Annual Meeting to be held on May 27, 2026. The Board asks stockholders to vote on election of directors, ratification of Ernst & Young as auditor, a non-binding say-on-pay, a one-time repricing of certain employee and consultant stock options covering 9,540,140 shares with exercise prices from $5.44 to $30.98, and a proposed 7,700,000-share increase to the 2014 Equity Incentive Award Plan reserve.

The repricing would reset Eligible Options to the closing price on the meeting date and extend option terms by ten years, but would restore original exercise prices if options are exercised or service terminates before May 27, 2027. The Board recommends a vote "FOR" all proposals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
proxy
-
Rhea-AI Summary

Coherus Oncology Inc — The Vanguard Group filed Amendment No. 5 to Schedule 13G/A reporting 0 shares beneficially owned of Coherus Oncology common stock, representing 0% of the class. The filing includes a disclosure that Vanguard underwent an internal realignment on January 12, 2026 leading to disaggregated reporting. The form is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.81%
Tags
ownership
-
Rhea-AI Summary

Coherus Oncology, Inc. describes a strategic shift to become a fully integrated commercial-stage oncology company centered on its PD‑1 inhibitor LOQTORZI for nasopharyngeal carcinoma and a focused immuno-oncology pipeline.

LOQTORZI is FDA‑approved in the United States for first‑line metastatic or recurrent locally advanced nasopharyngeal carcinoma in combination with cisplatin and gemcitabine, and as monotherapy after platinum-based chemotherapy. The company estimates up to 2,000 recurrent or metastatic NPC patients in the United States are eligible, representing a $250 million market opportunity.

Coherus highlights mid‑stage clinical candidates casdozokitug (anti‑IL‑27) and tagmokitug (anti‑CCR8), both intended for combination use with LOQTORZI and partners’ agents across liver, head and neck, colorectal and other cancers. It reports multiple collaborations and licenses, including Junshi Biosciences, Apotex, Janssen, Adimab and Vaccinex.

The company notes completion of the divestiture of its UDENYCA biosimilar franchise in April 2025, reinforcing its oncology focus. As of June 30 2025, aggregate market value of common stock held by non‑affiliates was approximately $81.9 million, and shares outstanding were 149,889,902 as of February 28 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
annual report
Rhea-AI Summary

Coherus Oncology, Inc. reported 2025 results showing strong product growth alongside continued losses from continuing operations. LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024, helping lift total net revenue from continuing operations to $42.2 million from $26.4 million.

The company reduced secured and convertible debt by about 90% over 2024–2025, from $480 million to $38.8 million, and ended 2025 with $172.1 million in cash, cash equivalents and marketable securities. Research and development spending from continuing operations increased to $108.9 million, reflecting investment in pipeline candidates casdozokitug and tagmokitug, while selling, general and administrative expenses declined to $100.6 million.

Net loss from continuing operations for 2025 narrowed to $183.1 million, or $(1.56) per diluted share, from $215.4 million, or $(1.88) per share, in 2024. Including large gains from discontinued operations, Coherus reported full-year net income of $168.0 million for 2025 compared with $28.5 million in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
current report
-
Rhea-AI Summary

Coherus Oncology, Inc. completed an underwritten public offering of its common stock. The company sold 28,600,000 shares at a price to the public of $1.75 per share, with underwriters purchasing at $1.645 per share, generating approximately $47.0 million in net proceeds before expenses.

The underwriters also received a 30-day option to buy up to an additional 4,290,000 shares to cover any over-allotments. Coherus, its directors, executive officers and certain affiliated stockholders agreed to a 60-day lock-up on additional common stock sales, subject to specified exceptions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.24%
Tags
current report
-
Rhea-AI Summary

Coherus Oncology, Inc. is conducting a primary offering of 28,600,000 shares of common stock at $1.75 per share, with expected net proceeds of about $46.5 million, plus a 30‑day option for underwriters to buy up to 4,290,000 additional shares.

The company plans to use the funds to support commercialization of LOQTORZI, advance clinical development of its oncology pipeline, and for working capital and general corporate purposes. Preliminary 2025 results show estimated net revenue of $42.2 million, up from $26.4 million in 2024, driven largely by $40.8 million of LOQTORZI sales.

Cash, cash equivalents and marketable securities are estimated at $172.1 million as of December 31, 2025, and Coherus expects this liquidity to fund operations through the end of 2026, while still recording a loss from continuing operations for the fourth quarter of 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
prospectus
Rhea-AI Summary

Coherus Oncology is launching a public offering of common stock from its existing shelf registration. The company plans to use proceeds to support commercialization of LOQTORZI, advance clinical development of its oncology pipeline, and for working capital and general corporate purposes.

Preliminary unaudited results for 2025 show net revenue from continuing operations of about $12.7 million for Q4 (vs. $7.7 million a year earlier) and $42.2 million for the full year (vs. $26.4 million), with LOQTORZI contributing most of these amounts. Cash, cash equivalents and marketable securities were approximately $172.1 million as of December 31, 2025, which the company expects will fund operations through the end of 2026.

Coherus describes positive clinical data for LOQTORZI in nasopharyngeal cancer, including a Phase 3 trial showing median overall survival of 64.8 months with LOQTORZI plus chemotherapy versus 33.7 months with chemotherapy alone and an observed 38% reduction in risk of death. Additional Phase 2 data for casdozokitug in liver cancer showed an overall response rate of 38% and complete response rate of 17% in combination therapy, with no new safety signals reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.90%
Tags
prospectus
-
Rhea-AI Summary

Coherus Oncology, Inc. received a Schedule 13G reporting that the Timothy G. Youngquist 2020 Irrevocable Trust beneficially owns 7,850,800 shares of its common stock. This represents 6.49% of the outstanding common shares, based on 120,871,013 shares outstanding as of October 31, 2025.

The trust has sole power to vote and dispose of these 7,850,800 shares. The position includes 560,000 shares underlying call options that are counted as beneficially owned because they are exercisable within 60 days. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.86%
Tags
ownership
-
Rhea-AI Summary

Coherus Oncology, Inc. entered into a clinical supply agreement with Janssen Research & Development, LLC to support a Phase 1b study in metastatic castration-resistant prostate cancer. The trial will evaluate Coherus’ investigational anti-CCR8 cytolytic monoclonal antibody tagmokitug (CHS-114) in combination with Janssen’s T-cell engaging bispecific antibody pasritamig.

Under the agreement, Janssen will supply pasritamig, while Coherus will act as sponsor of the Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer. Each company keeps all commercial rights to its own compound, whether used alone or in combination therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
current report
Rhea-AI Summary

The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 10,028,893 shares of Coherus Oncology Inc common stock, representing 8.29% of the class. Vanguard reports no sole voting or dispositive power, with 815,663 shares subject to shared voting power and 10,028,893 shares subject to shared dispositive power.

Vanguard explains that an internal realignment on January 12, 2026 means certain subsidiaries or business divisions are expected to report holdings separately on a disaggregated basis, while pursuing the same investment strategies as before. The holdings include securities in the form of rights, and Vanguard states its clients have the right to receive dividends or sale proceeds, with no single other person’s interest exceeding 5%. Vanguard certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.30%
Tags
ownership

FAQ

How many Coherus Oncology (CHRS) SEC filings are available on StockTitan?

StockTitan tracks 56 SEC filings for Coherus Oncology (CHRS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Coherus Oncology (CHRS)?

The most recent SEC filing for Coherus Oncology (CHRS) was filed on November 9, 2026.